| Literature DB >> 34093888 |
Jijo Lukose1, Sanoop Pavithran M1, Mithun N1, Ajaya Kumar Barik1, Keerthilatha M Pai2, V K Unnikrishnan1, Sajan D George3, V B Kartha1, Santhosh Chidangil1.
Abstract
Human saliva can be treated as a pool of biological markers able to reflect on the state of personal health. Recent years have witnessed an increase in the use of optical devices for the analysis of body fluids. Several groups have carried out studies investigating the potential of saliva as a non-invasive and reliable clinical specimen for use in medical diagnostics. This brief review aims to highlight the optical technologies, mainly surface plasmon resonance (SPR), Raman, and Fourier transform infrared (FTIR) spectroscopy, which are being used for the probing of saliva for diverse biomedical applications. Advances in bio photonics offer the promise of unambiguous, objective and fast detection of abnormal health conditions and viral infections (such as COVID-19) from the analysis of saliva.Entities:
Keywords: COVID-19; FTIR; HPLC-LIF; Photonics; Raman spectroscopy; SERS; SPR; Saliva
Year: 2021 PMID: 34093888 PMCID: PMC8170462 DOI: 10.1007/s12551-021-00807-8
Source DB: PubMed Journal: Biophys Rev ISSN: 1867-2450
Fig. 1Schematic illustration of the major salivary glands and their contributions to the components of saliva. Reprinted with permission from (Roblegg et al. 2019)
Fig. 2A) Prism coupling configuration of SPR, where a light beam impinges on a thin metallic film deposited on a prism. P-polarized light absorbed by the surface plasmon is seen from a minimum in the reflection spectra. B) Representation of the localized surface plasmon on nanoparticles and absorbance spectra obtained for binding events on nanoparticles. Reproduced from (Masson 2020) with permission from The Royal Society of Chemistry. (b) SPRi instrument developed for biosensing. Reproduced from (Lukose et al. 2018)
Fig. 3(a) SPR procedure for ABH antigen detection in saliva. (b, c) SPR sensorgrams of ABH antigen detection in red blood cells (direct assay) (b) and saliva (sandwich assay) (c). Reproduced from Ref. (Peungthum et al. 2017)
Fig. 4(a). Schematics of plasmon-enhanced fluorescence spectroscopy biosensor with a detail of sensor chip with poly(HPMA-co-CBMAA) brush functioning as a binding matrix. (b). Example of kinetics of fluorescence signal for negative and highly positive saliva samples. Reproduced under a Creative Commons Attribution (CC-BY) License from (Riedel et al. 2017)
Fig. 5Vibrational energy level diagram of a molecular system with Raman scattering process and infrared absorption
Fig. 6Flow-focusing microfluidic device used for controlled Ag-NP aggregation. (A) Ag-NP suspension, a saliva sample, and salt solution are loaded in the device and driven through it by a vacuum pump. (B) At the flow-focusing junction, the sample stream is enveloped by the side-streams and diffusion drives lateral mass transport between the laminar flows, here visualized with a fluorescent dye. (C) Schematic of the reaction: Ag NP, analyte and salt solution are introduced to the channel from the left and flow toward the right. Analyte molecules resident in the focused stream diffuse laterally into the side flows. Salt ions also diffuse into the colloid stream inducing controlled nanoparticle aggregation, creating SERS-active clusters that convect downstream. Interrogating the region rich in colloid dimers, which provide intense plasmonic enhancement, we are able to achieve optimal SERS-based detection. Reprinted from (Andreou et al. 2013) Copyright (2013) American Chemical Society
Fig. 7Curve-fitting analysis of the 900–1200 cm−1 spectral interval (a—control group, b—TM patients) and amide I/II with second derivative spectra (c—control group, d—TM patients) profiles together with (e) averaged ATR-FTIR spectra of saliva samples (black line—control group, red line—TM patients). Spectra were averaged from five healthy volunteers and five salivary gland tumour patients spectra, respectively. Reprinted from (Paluszkiewicz et al. 2020)
Fig. 8(a) Schematic of the experimental set up and (b) White light spectrum of pure H2O and H2O + α-amylase samples. Reproduced from (Chidangil et al. 2007) under Creative Commons (CC BY 4.0)
Fig. 9(a) Typical pre-processed saliva chromatograms of normal, premalignant, and malignant classes (normalized with respect to 1200 s peak). (b) Expanded (five times) chromatograms in (a). Reprinted from (Patil et al. 2013)
Fig. 10(a) Schematic illustration of reflectometric detection principle for influenza virus in human saliva using nanoimprint lithography (NIL)-based two-dimensional (2D) photonic crystal (PC). (b) Experimental procedure for the reflectometric detection of influenza virus in human saliva using antibody-immobilized 2D-PC. Reprinted from (Endo et al. 2010)
Fig. 11Potential diagnostic value of saliva and transmission of 2019-nCoV. Possibly binding to host-cell receptor of ACE2 expressed in salivary glands and tongue, 2019-nCoV is detected in saliva. Combined with infectious fluids from respiratory system, 2019-nCoV via large saliva droplets sets up short-distance transmission and hardly form long-distance aerosol transmission outdoors due to complicated physical and biological decay. Prevention of droplets formation, implementation of air disinfection, and blockage of droplets acquisition could possibly slow down 2019-nCoV dissemination (Reprinted from (Xu et al. 2020c) Under Creative Common License (http://creativecommons.org/licenses/by/4.0/)
Selected references on use of photonics/optical spectroscopy-based studies on saliva for clinical and other applications. (Various cancers)
| S. No | Method | Applications | Year and ref | Sensitivity/L.O.D |
|---|---|---|---|---|
| 1 | SERS | Oral Cancer: Saliva +Au nanoparticles. PCA of Raman | 2020 [Fălămaș et al. | _ |
| 2 | SERS | Oral Cancer healthy, mild and moderate dysplasia | 2020 [(Muro et al. | _ |
| 3 | ATR-FTIR | Salivary exosomes;machine learning PCA &SVM | 2020 [Su and Lee | _ |
| 4 | ATR-FTIR | Salivary gland tumor (tumor mixus, TM) | 2020 [Paluszkiewicz et al. | _ |
| 5 | Raman | Oral Squamous cell carcinoma | 2020 [Falamas et al. | 93.6% |
| 6 | ATR-FTIR | Saliva for breast cancer | 2020 [Ferreira et al. | 94% |
| 7 | SERS | POC handheld. (S100P) mRNA in whole saliva; biomarker for oral cancer. | 2019 [Han et al. | L.O.D in free solution:1.1 nM In VFC L.O.D:10nM |
| 8 | FTIR | Diagnosis of lung and breast cancers | 2019 [Bel’skaya et al. | _ |
| 9 | FTIR | Salivary exosomes; oral cancer (OC) | 2019 [Zlotogorski-Hurvitz et al. | 100% |
| 10 | General | Saliva for various cancers | 2019 [Kaczor-Urbanowicz et al. | Lung cancer sensitivity 93.75% |
| 11 | ATR-FTIR | Oral cancer diagnostics. Spectra of Salivary Exosomes | 2019 [Dekel et al. | 100% |
| 12 | SERS | Liquid biopsy for various cancers. | 2019 [Zhang et al. | miRNAs in liver cancer L.O.D 10fM |
| 13 | SERS | Ovarian cancer | 2018 [(de Jesús Zermeño-Nava et al. | 80% |
| 14 | Fluorescence | Oral pre-cancer | 2018 [Kumar et al. | OSCC to normal 91%, OSMF to normal 92% |
| 15 | LIF | salivary proteins labelled with Cy3 fluorescent dye and detected by fluorescence | 2018 [Liu et al. | 60% |
| 16 | UV-Visible Absorption | Saliva in leukaemia | 2018 [Joudah et al. | _ |
| 17 | UV- Fluorescence | Steady and excited state kinetics; normal, oral premalignant and malignant subjects | 2018 [Yuvaraj et al. | 86.6% |
| 18 | SERS | Sialic acid (SA) in saliva; breast cancer Detection. | 2017 [Hernández-Arteaga et al. | 94% |
| 19 | Spectrophotometry | Salivary levels of zinc, iron and copper in Head and Neck Cancer | 2017 [George et al. | _ |
| 20 | SERS | Nasopharyngeal carcinoma NPC. SERS with PCA-LDA; non-invasive detection of NPC | 2016 [Qiu et al. | 86.7% |
| 21 | SPR | Recombinant human matrix metalloproteinases-9 (MMP-9); tumor progression and metastasis; saliva | 2016 [Mohseni et al. | L.O.D : 8 pg/ml |
| 22 | SERS | Breast cancer | 2015 [Feng et al. | Malignant 74.19% |
| 23 | HPLC-LIF | Various cancers | 2015 [Patil et al. | L.O.D : femto-moles |
| 24 | AAS. | Copper, iron, zinc and manganese in oral submucous fibrosis | 2015 [Okade et al. | _ |
| 25 | Fluorescence | Oral Cancer | 2014 [Yuvaraj et al. | Emission spectra sensitivity 85.7% |
| 26 | Fluorescence | Quantum Dots in Breast Cancer | 2014 [Jokerst et al.] | L.O.D CEA: 0.02 ng/ml |
| 27 | HPLC-LIF | Salivary protein markers; Oral cancer | 2018 [Zaorska et al. | 79% |
| 28 | SPR | Carbohydrate antigen 15-3 (CA15-3) in saliva | 2012 [Liang et al. | L.O.D : 2.5 U/ml |
| 29 | SERS | Saliva lung cancer | 2011 [Li et al. | 94% |
| 30 | Optical | Cancers | 2008 [Tan et al. 2011] | L.O.D IL-8: 4 fM |
| 31 | SERS | 5-fluorouracil: Chemotherapy drug; for solid tumors and colorectal carcinoma | 2008 [Farquharson et al. | L.O.D: 2 μg/ml |
| 32 | SERS | 5-Fluorouracil: Chemotherapy drug; for solid tumors and colorectal carcinoma | 2005 [Farquharson et al. | L.O.D : 150 ng/ml |
| 33 | SPR | Interleukin-8(IL-8).Oropharyngeal squamous cell carcinoma (OSCC) | 2005 [Yang et al. | L.O.D : 2.5 pM |
Selected references on use of photonics/optical spectroscopy-based studies on saliva for clinical and other applications. (Viral and other pathogen-related disorders)
| 1 | SERS | Spike protein (S protein) of SARS-CoV-2 in human saliva | 2020 [Jinglin et al. | _ |
|---|---|---|---|---|
| 2 | Fluorescence | Coronavirus diagnosis | 2020 [Bioptics World Editors | _ |
| 3 | SERS, SPR | H1N1, HAdV and SARS-CoV-2 | 2020 [Cui and Zhou | SERS:50 and 10 pfu mL−1 SPR:0.22 pM |
| 4 | Raman | Detection of RNA viruses in saliva. | 2020 [Desai et al. | 92.5% |
| 5 | SERS | SARS-CoV-2 | 2020 [Yacaman et al. | _ |
| 6 | SPR | Immunosensors: viruses, microbes, extracellular vesicles (EV) | 2020 [Choi et al. | _ |
| 7 | Interferometry | COVID- 19 saliva test | 2020 [Wallace | L.O.D miRNA: attomole(am) range, 4 CFU/mL for whole pathogen detection. |
| 8 | SERS | Pandemic H1N1 (pH1N1) virus in human saliva. | 2019 [Eom et al. | L.O.D : 1 PFU |
| 8 | SERS | Immunoassays for Detection of Botulinum Toxins | 2019 [Kim et al. | 5.7 ng/ml(Type A L.O.D) 1.3 ng/ml(Type B L.O.D) |
| 9 | SERS | Bacteria sensing | 2019 [Wang et al. | _ |
| 10 | SERS | Avian influenza virus- H3N2 | 2017 [Sun et al. | 102 TCID50/mL |
| 11 | SERS | Pyocyanin (PYO), biomarker for Pseudomonas infections; in saliva. | 2017 [Žukovskaja et al. | L.O.D: 0.5 μM |
| 12 | SPR | Avian influenza virus H5N1. | 2012 [Bai et al. | L.O.D : 0.128 HAU |
| 13 | Reflectometry | Influenza virus | 2010 [Endo et al. | L.O.D: 1 ng/ml |
Selected references on use of photonics/optical spectroscopy-based studies on saliva for clinical and other applications. (Other disorders)
| 1 | SERS | Saliva. Sjögren's syndrome (SjS) | 2020 [Moisoiu 2020] | 96.5% |
|---|---|---|---|---|
| 2 | ATR-IR | Periodontal Diseases | 2020 [Beyer-Hans et al. | _ |
| 3 | ATR-FTIR | Bio fluids including saliva; Review, clinical applications | 2020 [Naseer et al. | _ |
| 4 | Raman | Amyotrophic Lateral Sclerosis (ALS) diagnosis | 2020 [Carlomagno et al. | _ |
| 5 | SERS | Periodontitis, Sialic Acid (SA) | 2019 [Hernández-Cedillo et al. | 69.6% |
| 6 | SERS | To evaluate the activity of urease in saliva. Dental caries; helicobacter pylori infection | 2019 [Hu et al. | L.O.D: 2.35 μg/ml |
| 7 | SERS | biomarkers of bronchial inflammation in the saliva of children with asthma | 2019 [Zamora-Mendoza et al. | 85% |
| 8 | ATR-FTIR | Chronic kidney disease | 2019 [Rodrigues et al. | 92.8% |
| 9 | FTIR | Burning Mouth Syndrome | 2019 [Rodrigues et al. | _ |
| 10 | FTIR | Neonatal sepsis using saliva | 2019 [Yunanto et al. | _ |
| 11 | ATR-FTIR | Multiple dental caries | 2018 [Seredin et al. | _ |
| 12 | Plasmonics | Hepatitis B | 2017 [Riedel et al. | _ |
| 13 | IR | Saliva in healthy, chronic, and aggressive periodontitis | 2017 [Saranya | _ |
| 14 | Plasmonics | Hepatitis B | 2016 [Riedel et al. | _ |
| 15 | FTIR | Differentiation of chronic and aggressive Periodontitis | 2016 [Simsek Ozek et al. | 82% |
| 16 | ICP OES & ICP MS | Periodontal diseases. | 2016 [Herman et al. | L.O.D: 0.007 μg/l for Pb and 0.21 μg/l for Fe |
| 17 | Raman | Myocardial Infarction. Saliva spectroscopy; Multivariate analysis | 2015 [Cao et al. | 80.04% |
| 18 | FTIR | Saliva proteomic components in psoriatic and diabetic patients | 2015 [Bottoni et al. | _ |
| 19 | Fluorescence | Lithium in Bipolar disorder | 2011 [Kim et al. | _ |
| 20 | SPR | Mucin, Gingivitis, Periodontitis | 2007 [Fernández-González et al. | _ |
Selected references on use of photonics/optical spectroscopy-based studies on saliva for clinical and other applications. (Drugs)
| 1 | SERS | Detection of methamphetamine in saliva and urine | 2020 [Hong et al. | L.O.D: nM |
|---|---|---|---|---|
| 2 | SERS | Detection of morphine | 2020 [Li et al. | 2.4×10−4 |
| 3 | SERS | Tetrahydrocannabinol (THC) in human plasma and saliva | 2019 [Sivashanmugan et al. | L.O.D: 1pM |
| 4 | SERS | Tetrahydrocannabinol (THC) in saliva | 2019 [Sivashanmugan et al. | L.O.D: 10 ppm |
| 5 | SERS | Codeine and Fentanyl; in saliva and blood | 2019 [Shende et al. | L.O.D: 0.5 μg/ml |
| 6 | SERS | Plasmonic capsules based SERS: methamphetamine (MA), in human saliva | 2019 [Su et al. | 67.4% |
| 7 | SERS | Ultra-traces of cocaine | 2018 [D’Elia et al. | L.O.D: 10ng/ml |
| 8 | SERS | Detection of drug-related biomarkers | 2015 [Yang et al. | L.O.D: 100 nM |
| 9 | SERS | Cocaine; in saliva. | 2015 [Dana et al. | L.O.D: 25 ng/ml |
| 10 | SERS | Illicit Drugs; in saliva | 2014 [Shende et al. | _ |
| 11 | IR | Cocaine in saliva | 2014 [Hans et al. | L.O.D: 100 ng/ml |
| 12 | SERS | methamphetamine | 2013 [Andreou et al. | L.O.D: 10 nM |
| 13 | ATR-IR | Cocaine in saliva | 2012 [Hans et al. | _ |
| 14 | SERS | Drugs of abuse; in saliva | 2011 [Inscore et al. | L.O.D : 1 ppm |
| 15 | SERS | Cocaine in saliva | 2011 [Farquharson et al. | L.O.D: 50 ng/ml |
| 16 | SPR | pharmaceutical compounds cocaine and MDMA(3,4-methylenedioxy-methamphetamine) | 2010 [Sonny et al. | _ |
| 17 | Raman | Saliva of narcotic users | 2009 [Anyu et al. | _ |
| 18 | SPR | Antiepileptic drug (AED) phenytoin | 2007 [Fu et al. | L.O.D: 50 nM |
| 19 | SERS | Drugs and metabolites; in saliva | 2005 [Shende et al. | _ |
Selected references on use of photonics/optical spectroscopy-based studies on saliva for clinical and other applications. (Other abnormal conditions)
| 1 | LSPR | Cortisol, stress biomarker | 2020 [Jo et al. | L.O.D: 0.1 nM |
|---|---|---|---|---|
| 2 | UV Absorption | Stress biomarkers in different body fluids | 2019 [Ray and Steckl | L.O.D of cortisol: 0.5 μM |
| 3 | SERS, LIF, SPR | Diseases, drugs, general health | 2019 [Ilea et al. | _ |
| 4 | FTIR | Real-time checking of response to stress | 2016 [Caetano Júnior et al. | _ |
| 5 | SPR | Hormones (Cortisol, Testosterone) | 2014 [Stevens et al. 2014, Mitchell and Lowe | L.O.D of cortisol: 1 ng/ml L.O.D of Testosterone: 29 pg/ml |
| 6 | SPR | Cortisol | 2014 [Tahara et al. | L.O.D: 38 ppt |
| 7 | SPR | Cathespin G, Immune response | 2011 [Gorodkiewicz et al. | L.O.D: 0.12 ng/ml |
| 8 | FTIR | Saliva of normal and diabetic pregnant women in each trimester. | 2011 [Sultana et al. | _ |
| 9 | SPR | Cathespin D | 2010 [Gorodkiewicz and Regulska | L.O.D: 0.12 ng/ml |
| 10 | ATR-FTIR | Saliva biomarker; exercise induced stress. Real-time checking of response to stress. | 2010 [Khaustova et al. | _ |
| 11 | SPR | Cortisol and cortisone | 2009 [Frasconi et al. | L.O.D: 10 μg/l |
Selected references on use of photonics/optical spectroscopy-based studies on saliva for clinical and other applications. (Other applications)
| 1 | IR | Age and gender | 2020 [Bel’skaya et al. | _ |
|---|---|---|---|---|
| 2 | AAS | Metal residuals in saliva: orthodontic Appliances | 2020 [Curro, and Bilello | L.O.D : μg/l |
| 3 | IR | Spectral features in tobacco smoking, periodontal diseases, and gender. | 2019 [Derruau et al. | _ |
| 4 | AAS | Release of nickel, chromium, and zinc in saliva; Use of orthodontic appliances | 2019 [Quadras et al. | _ |
| 5 | SERS | Effects of low-dose irradiation on saliva | 2019 [Colceriu-Șimon et al. | _ |
| 6 | LIBS | Calcium in saliva | 2019 [Zahroh et al. | _ |
| 7 | IR | Saliva composition | 2018 [Bel’skaya et al. | _ |
| 8 | ATR-FTIR | Forensic, body fluids, including Saliva | 2018 [Takamura et al. | _ |
| 9 | SPR | ABH antigen detection in saliva. | 2017 [Peungthum et al. | _ |
| 10 | LSPR | Wine astringency. Interaction of red wine and saliva | 2017 [Guerreiro et al. | L.O.D : 1 μmol/L |
| 11 | LSPR | Monitoring the pH of saliva | 2017 [Luo et al. | wavelengths of 665 nm and 785 nm—the sensitivities were 0.0299 a.u./pH (a.u. = arbitrary unit) with a linear range of pH = 5–8 and 0.0234 a.u./pH with linear range of pH = 2–8, respectively |
| 12 | FTIR | Effect of smoking cessation on saliva | 2017 [Rodrigues et al. | _ |
| 13 | TRLFS | ingestion of radioactive contaminants, time-resolved laser-induced fluorescence spectroscopy | 2017 [Barkleit et al. | _ |
| 14 | Raman | Forensic body fluid identification | 2016 [Muro et al. 2016] | _ |
| 15 | Raman | Sex determination based on saliva spectrum; forensic | 2016 [Muro et al. | 92% |
| 16 | IR, Raman | Forensic analysis | 2015 [Zapata et al. | _ |
| 17 | SPRi-MS | Protein biomarkers salivary α-amylase and lysozyme. | 2015 [Musso et al. | _ |
| 18 | Raman | Forensic analysis | 2010 [Virkler and Lednev | _ |